Immunoprecise Stock Analysis

IPA -  USA Stock  

USD 6.77  0.60  8.14%

The big decline in price over the last few months for Immunoprecise Antibodiesmay raise some interest from investors. The stock closed today at a share price of 6.77 on very low momentum in trading volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Immunoprecise Antibodies or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.82. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Immunoprecise Antibodies partners.
Please see Risk vs Return Analysis.

Search Stock Analysis 

 
Refresh
The Immunoprecise Antibodies stock analysis report makes it easy to digest most publicly released information about Immunoprecise Antibodies and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Immunoprecise stock analysis module also helps to analyze the Immunoprecise Antibodies price relationship with some important fundamental indicators such as market cap and management efficiency.

Immunoprecise Stock Analysis Notes

The company had not issued any dividends in recent years. Immunoprecise Antibodies had a split on the 30th of May 2013. ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. To learn more about Immunoprecise Antibodies call the company at 250 483 0308 or check out http://www.immunoprecise.com.

Immunoprecise Antibodies Quarterly Cost of Revenue

953,847Share

Immunoprecise Antibodies Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Immunoprecise Antibodies' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunoprecise Antibodies or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Immunoprecise Antibodies generates negative expected return over the last 90 days
Immunoprecise Antibodies has high historical volatility and very poor performance
The company reported the last year's revenue of 17.18 M. Reported Net Loss for the year was (3.25 M) with profit before taxes, overhead, and interest of 7.95 M.
Immunoprecise Antibodies has a frail financial position based on the latest SEC disclosures
Latest headline from www.equities.com: ImmunoPrecise Antibodies Ltd gains 2.1450 percent for June 15 - Equities.com

Immunoprecise Antibodies SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Immunoprecise Antibodies prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Immunoprecise Antibodies investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Immunoprecise Antibodies specific information freely available to individual and institutional investors to make a timely investment decision.

Immunoprecise Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Immunoprecise Antibodies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunoprecise Antibodies backward and forwards among themselves. Immunoprecise Antibodies' institutional investor refers to the entity that pools money to purchase Immunoprecise Antibodies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Ingalls Snyder LlcCommon Shares517.2 K5.1 M
Awm Investment Company IncCommon Shares478 K4.7 M
Ikarian Capital LlcCommon Shares150 K1.5 M
Jpmorgan Chase CoCommon Shares44.3 K435 K
Credit Suisse Ag 1Common Shares33.4 K328 K
Marshall Wace LlpCommon Shares33.4 K325 K
Morgan StanleyCommon Shares23.7 K232 K
Note, although Immunoprecise Antibodies' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunoprecise Market Capitalization

The company currently falls under 'Small-Cap' category with total capitalization of 142.64 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunoprecise Antibodies's market, we take the total number of its shares issued and multiply it by Immunoprecise Antibodies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Immunoprecise Profitablity

Immunoprecise Antibodies' profitability indicators refer to fundamental financial ratios that showcase Immunoprecise Antibodies' ability to generate income relative to its revenue or operating costs. If, let's say, Immunoprecise Antibodies is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Immunoprecise Antibodies' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Immunoprecise Antibodies' profitability requires more research than a typical breakdown of Immunoprecise Antibodies' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of (18.93) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (31.16) %, which entails that for every $100 of revenue, it lost -0.31.
Last ReportedProjected for 2021
Return on Average Assets(0.16) (0.17) 
Return on Average Equity(0.27) (0.29) 
Return on Invested Capital(1.56) (1.68) 
Return on Sales(0.39) (0.42) 

Management Efficiency

The entity has Return on Asset of (9.67) % which means that on every $100 spent on asset, it lost $9.67. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (13.93) %, meaning that it generated no profit with money invested by stockholders. Immunoprecise Antibodies management efficiency ratios could be used to measure how well immunoprecise antibodies manages its routine affairs as well as how well it operates its assets and liabilities. As of June 19, 2021, Return on Average Assets is expected to decline to -0.17. In addition to that, Return on Average Equity is expected to decline to -0.29. Immunoprecise Antibodies Total Assets are projected to decrease significantly based on the last few years of reporting. The past year's Total Assets were at 24.54 Million. The current year Current Assets is expected to grow to about 7.1 M, whereas Assets Non Current are forecasted to decline to about 17.6 M.
Last ReportedProjected for 2021
Book Value per Share 1.00  1.06 
Tangible Assets Book Value per Share 0.73  0.73 
Tangible Asset Value12.7 M12.9 M

Technical Drivers

As of the 19th of June, Immunoprecise Antibodies retains the risk adjusted performance of (0.05), and Market Risk Adjusted Performance of 0.5705. Immunoprecise Antibodies technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Immunoprecise Antibodies, which can be compared to its competitors. Please check out Immunoprecise Antibodies maximum drawdown, and the relationship between the information ratio and downside variance to decide if Immunoprecise Antibodies is priced fairly, providing market reflects its last-minute price of 6.77 per share. Given that Immunoprecise Antibodies has jensen alpha of (0.53), we strongly advise you to confirm Immunoprecise Antibodies's regular market performance to make sure the company can sustain itself at a future point.

Immunoprecise Antibodies Price Movement Analysis

The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Mid-point over period is an average of Immunoprecise Antibodies highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Immunoprecise Antibodies Technical and Predictive Indicators

Immunoprecise Antibodies Forecast Models

Immunoprecise Antibodies time-series forecasting models is one of many Immunoprecise Antibodies' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunoprecise Antibodies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Immunoprecise Antibodies Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunoprecise Antibodies stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunoprecise shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Immunoprecise Antibodies. By using and applying Immunoprecise Stock analysis, traders can create a robust methodology for identifying Immunoprecise entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(0.0368) (0.0397) 
Gross Margin 0.66  0.65 
Profit Margin(0.40) (0.44) 
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Immunoprecise Antibodies to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Crypto Correlations Now

   

Crypto Correlations

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
All  Next Launch Module
Please see Risk vs Return Analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Immunoprecise Antibodies Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Equity Search
Search for activelly-traded equities including funds and ETFs from over 30 global markets
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.